Castle's first disease target is atopic dermatitis, with the goal to develop a test that can predict future flare-ups of the disease.

NEW YORK – Visby Medical announced Tuesday that it has raised about $55 million in a recent financing round with the total potentially reaching $65 million.

NEW YORK — EDX Medical Group said on Monday that it has a signed a memorandum of understanding with UK-based healthcare group Spire Healthcare around diagnostic products and testing services.

NEW YORK – Scope Biosciences has secured €1 million ($1.2 million) in follow-on investment to scale its molecular diagnostics platform. The diagnostics developer said Monday that the investment from ...

The acquisition is intended to expand the French firm's presence in sequencing-based infectious disease testing.

Last week, readers were most interested in a story about reports of a possible sale by Thermo Fisher Scientific of parts of its diagnostics business.

The Birmingham, UK, firm hopes to develop a broader test menu with industry partners, using AI and machine-learning approaches.

The company uses artificial intelligence to detect metabolic patterns from urine samples that indicate prostate cancer.